Antipsychotics and Antiemetics Drive Pediatric Drug-Induced Dystonia

Navigating Acute Movement Disorders in Pediatric Emergency Care

Acute movement disorders in the pediatric emergency department often present a diagnostic challenge, as they can mimic life-threatening neurological conditions such as botulism (a neurotoxin-mediated descending paralysis) or status epilepticus [1, 2, 3]. While dystonia (involuntary muscle contractions causing repetitive movements or abnormal postures) is a recognized feature of chronic conditions like cerebral palsy, its acute onset is frequently an adverse drug reaction to medications used for psychiatric or gastrointestinal indications [4, 5, 6]. These episodes are often triggered by pharmacological agents that interfere with dopaminergic pathways, including certain antipsychotics and antiemetics [4, 7]. Clinicians must distinguish these drug-induced events from more severe etiologies to avoid unnecessary invasive workups and to initiate rapid stabilization using agents such as biperiden (an anticholinergic medication used to block excessive cholinergic activity) [4]. A recent retrospective study offers precise clinical data on the specific risk factors, temporal patterns, and physical phenotypes associated with these acute presentations, providing a roadmap for faster diagnosis and treatment at the bedside.

Profiling the Patient Cohort and Clinical Phenotypes

To characterize the presentation of drug-induced acute dystonia in a pediatric population, researchers conducted a retrospective observational study tracking 79 patients who presented to a tertiary pediatric emergency department between October 2022 and March 2025. The cohort ranged in age from 1 month to 18 years. To better understand the clinical manifestations, the authors categorized the patients into two distinct cohorts based on their physical presentation. Group I consisted of patients with focal or segmental dystonia (involuntary contractions limited to a single body region or two contiguous regions), while Group II included those with multifocal or generalized dystonia (contractions involving two or more non-contiguous regions or the entire body).

Demographic analysis revealed that these reactions primarily affect school-aged children and adolescents, with Group I showing a median age of 11 years (IQR: 7 to 16) and Group II showing a median age of 10 years (IQR: 6 to 16). Clinical assessment demonstrated that focal dystonia was the most common clinical pattern observed in the cohort. Specifically, these localized muscle contractions affected the head and neck muscles in 61% of cases. For the practicing physician, this underscores the critical importance of recognizing orofacial and cervical spasms (such as torticollis or oculogyric crises) as potential drug-induced reactions rather than primary neurological events, allowing for rapid, targeted intervention.

Pharmacological Triggers and Temporal Patterns

The study identified three primary classes of medication responsible for inducing acute dystonia in the pediatric cohort, with dopamine-antagonizing agents representing the highest risk. Antipsychotics were the most commonly associated drug group, involved in 55.6% of cases, followed by antiemetics (26.6%) and psychostimulants (20.3%). Crucially, clinicians must recognize that these reactions are not strictly the result of overdose or misuse. The researchers noted that dystonia can develop even at therapeutic doses, making it a potential complication of routine pharmacological management in both psychiatric and primary care settings.

Furthermore, the researchers found a distinct correlation between the type of drug administered and the resulting clinical phenotype, which can assist in narrowing the differential diagnosis at the bedside. Specifically, dystonias associated with antiemetic drugs often show focal or segmental distribution. Within this category, the use of metoclopramide was significantly higher in Group I (the focal or segmental cohort) compared to the generalized cohort, demonstrating an odds ratio of 0.21 (95% CI: 0.04 to 0.99).

The timing of symptom onset provides another critical diagnostic window. The findings indicate that dystonia usually appears within the first 72 hours after starting the drug. Because these reactions occur so rapidly following exposure, obtaining a detailed medication history covering the preceding three days is essential for differentiating drug-induced dystonia from other acute neurological presentations.

Diagnostic Strategy and Management Outcomes

The diagnostic process in this cohort relied on the expertise of a pediatric emergency subspecialist who made the diagnosis of acute dystonia based on clinical findings rather than extensive laboratory or imaging studies. Because drug-induced acute dystonia can mimic serious etiologies such as tetanus, meningitis, or seizures, the researchers emphasized that obtaining a detailed drug history can facilitate the diagnostic process and prevent unnecessary, invasive testing. Identifying recent exposure to dopamine-blocking agents allows clinicians to confidently move directly to targeted therapy.

Management of these patients followed a uniform protocol, as all 79 patients were treated with parenteral biperiden (an anticholinergic agent administered via injection to rapidly restore the neurochemical balance between dopamine and acetylcholine in the basal ganglia). The study confirmed that parenteral biperiden is a fast and effective treatment option for reversing these extrapyramidal symptoms. For the practicing clinician, these findings reinforce the utility of parenteral anticholinergics as a first-line intervention in the pediatric emergency setting. By combining a targeted three-day medication history with prompt administration of biperiden, physicians can rapidly resolve distressing motor symptoms and avoid the prolonged emergency department stays associated with broader neurological workups.

References

1. Rao AK, Sobel J, Chatham‐Stephens K, Lúquez C. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recommendations and Reports. 2021. doi:10.15585/mmwr.rr7002a1

2. Lattanzi S, Leitinger M, Rocchi C, et al. Unraveling the enigma of new‐onset refractory status epilepticus: a systematic review of aetiologies. European Journal of Neurology. 2021. doi:10.1111/ene.15149

3. Wickström R, Taraschenko O, Dilena R, et al. International consensus recommendations for management of new onset refractory status epilepticus including febrile infection‐related epilepsy syndrome: Statements and supporting evidence. Epilepsia. 2022. doi:10.1111/epi.17397

4. Akkaya B, Erdem FŞ, Öztürk B, et al. Acute Drug-Induced Dystonia in Children: Risk Factors, Clinical Characteristics, and Emergency Management.. Pediatric emergency care. 2026. doi:10.1097/PEC.0000000000003624

5. Pringsheim T, Holler‐Managan Y, Okun MS, et al. Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019. doi:10.1212/wnl.0000000000007467

6. Fehlings D, Agnew B, Gimeno H, et al. Pharmacological and neurosurgical management of cerebral palsy and dystonia: Clinical practice guideline update. Developmental Medicine & Child Neurology. 2024. doi:10.1111/dmcn.15921

7. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. 2018. doi:10.1111/bdi.12609